-
Dec 10, 2024 | 
urologytimes.com | Jérémie Calais
In this video, Jeremie Calais, MD, PhD, highlights the key components of the report, “Standardized template for clinical reporting of PSMA PET/CT scans.” Calais is a nuclear medicine physician at the University of California, Los Angeles. Video Transcript:It's a table, basically, with boxes. It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together.
-
Nov 27, 2024 | 
urologytimes.com | Jérémie Calais
In this video, Jeremie Calais, MD, PhD, describes the rationale for the report, “Standardized template for clinical reporting of PSMA PET/CT scans.” Calais is a nuclear medicine physician at the University of California, Los Angeles. Video Transcript:Since the FDA approval of PSMA-PET/CT back in 2020 then subsequently followed by [18F]DCFPyL PET/CT and other PSMA-PET agents that became commercially available in 2021, even 2022—now we have 5 or 6 of them available.
-
Nov 12, 2024 | 
urologytimes.com | Jérémie Calais
In this video, Jeremie Calais, MD, PhD, highlights the background and key findings from the study, “Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy,” (NCT04928820), for which he served as the senior author. Calais is a nuclear medicine physician at the University of California, Los Angeles.
-
Oct 17, 2024 | 
nature.com | Jérémie Calais
AbstractFor prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT.
-
Oct 4, 2024 | 
jnm.snmjournals.org | Jérémie Calais |Michael Morris |Ayse Tuba Kendi |Arash Rezazadeh Kalebasty
BEST PRACTICES FOR AE MANAGEMENTThe safety of [177Lu]Lu-PSMA-617 in patients with mCRPC has been established in the phase III VISION study (3,7) and the phase II studies TheraP and RESIST-PC (8,9). In the VISION study, the most commonly reported AEs with [177Lu]Lu-PSMA-617 treatment were fatigue, dry mouth, nausea, and anemia (Supplemental Table 1; supplemental materials are available at http://jnm.snmjournals.org) (3), generally consistent with reports from TheraP (8) and RESIST-PC (9).
-
Mar 12, 2024 | 
onclive.com | Jérémie Calais
Jeremie Calais, MD, PhD, physician, nuclear medicine, associate professor, Department of Molecular and Medical Pharmacology, director, Theranostics Program, Ahmanson Translational Theranostics Division, faculty member, the Jonsson Comprehensive Cancer Center, faculty member, the Institute of Urologic Oncology, faculty member, the Physics and Biology in Medicine Graduate Program, University of California, Los Angeles (UCLA), UCLA Health, discusses controversies and unresolved questions in the...
-
Feb 12, 2024 | 
urotoday.com | Jérémie Calais
Read the Full Video TranscriptJeremie Calais: All right, now we're going to switch to the topic of imaging response or imaging progression, depending on how we want to see it, under PSMA targeted radiopharmaceutical therapy. So I want to start with conventional imaging and how we can also image with another imaging agent and PSMA targeted PET or SPECT, the response to lutetium PSMA therapy.
-
Feb 12, 2024 | 
urotoday.com | Jérémie Calais
Read the Full Video TranscriptJeremie Calais: Great overview, Mike, as always. I think my talk will just give more images on top of what Mike just said. So my presentation is about the PSMA PET selection criteria for patients for PSMA radiopharmaceutical therapy. We'll review the data, a little bit of the trial, a little bit like Mike just did, just putting more some visuals, I would say. Just to make sure we're all on the same page and make sure we understand the mechanism of action of that drug.
-
Jan 30, 2024 | 
urotoday.com | Jérémie Calais
Read the Full Video TranscriptPhillip Koo: Hi, my name is Philip Koo and welcome to UroToday. UCLA and UCSF hosted the first annual PSMA conference, which was a huge success, widely attended, amazing discussions, and really a lot of great actionable information for people interested in PSMA to take home and move forward with at their respective institutions.
-
Jan 30, 2024 | 
urotoday.com | Jérémie Calais
Read the Full Video TranscriptPhillip Koo: Hi, my name is Philip Koo and welcome to UroToday. UCLA and UCSF hosted the first annual PSMA conference, which was a huge success, widely attended, amazing discussions, and really a lot of great actionable information for people interested in PSMA to take home and move forward with at their respective institutions.
